Octreotide Sandoz (Octreotide)

Octreotide Sandoz is a somatostatin analogue that modulates hormone secretion in several endocrine conditions.

• Acromegaly: reduces growth hormone and IGF‑1 levels, helping control disease activity.
• Neuroendocrine tumors: controls symptoms related to hormone over‑production such as flushing and diarrhoea.
• Carcinoid syndrome: decreases flushing, wheezing and diarrhoea associated with serotonin excess.
• Vaso‑occlusive crises in sickle cell disease (investigational): may reduce the frequency of painful episodes.
• Prevention of postoperative pancreatic fistula: lowers pancreatic secretions after major abdominal surgery.

• Octreotide binds selectively to somatostatin receptor subtypes 2 and 5, inhibiting adenylate cyclase activity and reducing cyclic AMP formation. This receptor activation suppresses the release of several hormones and peptides, including growth hormone, insulin, glucagon, gastrin, and vasoactive intestinal peptide, thereby decreasing endocrine and exocrine secretions that drive disease processes.

Octreotide may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

• Gastrointestinal discomfort: nausea, abdominal cramping
• Injection site reactions: erythema, pain, induration
• Gallbladder abnormalities: biliary sludge or stones
• Metabolic changes: hyperglycaemia or hypoglycaemia
• Fatigue or headache

Serious or Rare Side Effects

• Pancreatitis
• Severe hyperglycaemia requiring insulin therapy
• Cardiac arrhythmias
• Acute gallbladder disease requiring surgery
• Anaphylactic reactions

Octreotide should be used with careful clinical monitoring and appropriate patient education.

• Dose adjustment: renal or hepatic impairment may require lower doses.
• Glycaemic monitoring: patients with diabetes may experience altered blood glucose levels.
• Gallbladder monitoring: long‑term therapy can promote biliary sludge formation.
• Cardiovascular assessment: monitor for bradyarrhythmias in patients with pre‑existing conduction disorders.
• Pregnancy and lactation: only use if the potential benefit outweighs risk; discuss with a specialist.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Octreotide can interact with several drug classes, affecting absorption, metabolism, or therapeutic outcomes.

Major Interactions (Avoid)

• Short‑acting somatostatin analogues: concurrent use may amplify hormonal suppression.
• Cytochrome P450 inducers: may reduce octreotide plasma concentrations.

Moderate Interactions (Monitor Closely)

• Insulin and oral hypoglycaemic agents: risk of hypoglycaemia or hyperglycaemia.
• Antiplatelet or anticoagulant drugs: increased risk of gallbladder‑related bleeding.
• Proton pump inhibitors: may alter gastrointestinal absorption of the drug.
• Diuretics: potential electrolyte disturbances when combined with octreotide‑induced fluid shifts.
• Radiolabelled somatostatin analogues for imaging: timing adjustments may be required to avoid diagnostic interference.